Related Experiment Video
Updated: Jul 26, 2025
09:38
A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
13.9K
Citrate Phosphate Dextrose Alters Coagulation Dynamics Ex Vivo
Jacob B Schriner1, Atharwa Mankame2, Scott D Olson3
1Department of Surgery, Center for Translational Injury Research, McGovern Medical School at The University of Texas Health Science Center at Houston, Houston, Texas.
The Journal of Surgical Research
|June 18, 2023
Summary
Citrate-phosphate-dextrose (CPD) does not impact platelet function or clot strength. However, CPD may alter clot dynamics by reducing thrombin generation compared to blue top citrate (BTC) tubes.
Area of Science:
- Hematology
- Transfusion Medicine
- Biochemistry
Background:
- Citrate-phosphate-dextrose (CPD) is the standard anticoagulant for blood products in the US.
- Limited research exists on CPD's effect on post-transfusion blood function.
Purpose of the Study:
- To compare the effects of CPD versus standard blue top citrate (BTC) tubes on platelet activation and clot formation.
- To investigate the impact of CPD on key hemostatic parameters.
Main Methods:
- Blood samples from healthy donors were collected and anticoagulated with either CPD or BTC.
- Platelet activation was assessed using flow cytometry (FC).
- Global clot formation was evaluated using thromboelastography (TEG) and a clot contraction assay (zFlex).
Main Results:
- Platelet activation showed minimal differences between CPD and BTC, with higher CD62p expression in CPD upon stimulation (P=0.007).
- TEG revealed significantly longer reaction time (R-time) and kinetics time (K-time) in CPD samples (P<0.001 for both).
- Maximum clot amplitude (MA) and clot contraction strength were similar between CPD and BTC groups (P=0.33 and P=0.39, respectively).
Conclusions:
- CPD does not appear to impair platelet function or ultimate clot strength.
- CPD may influence clot dynamics by potentially attenuating thrombin generation, as indicated by altered TEG parameters.
- Further research is needed to fully elucidate the clinical implications of these findings.
Related Concept Videos
01:09Coagulation
7.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.2K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
8.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.4K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:18Effects of EDTA on End-Point Detection Methods
314
Different methods, such as visual observance of metal-ion indicators, spectroscopic techniques, and potentiometric methods, can determine the endpoint of an EDTA titration.
In the visual method, metal-ion indicators (metallochromic dyes), which have distinct colors in their free and complex forms, are added to the mixture to signal the titration's end point. They form stable complexes with metal ions, but these complexes are weaker than the corresponding metal–EDTA complexes. As a...
In the visual method, metal-ion indicators (metallochromic dyes), which have distinct colors in their free and complex forms, are added to the mixture to signal the titration's end point. They form stable complexes with metal ions, but these complexes are weaker than the corresponding metal–EDTA complexes. As a...
314